GlassScriptPhysician profile
Christopher M Morgan
NPI 1891341335
$3,889.09
in general payments reported to CMS, 2019-2025
28 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $993 · 2022: $941 · 2023: $823 · 2024: $726 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $414.19 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $401.47 | 2022-2025 | Verquvo, Winrevair |
| Amgen INC. | $297.47 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.70 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $275.10 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $271.27 | 2021-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $269.65 | 2021-2024 | Xarelto |
| Abbvie INC. | $224.99 | 2021-2023 | |
| United Therapeutics Corporation | $214.68 | 2021-2025 | Tyvaso, Tyvaso |
| Esperion Therapeutics, INC. | $178.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.64 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $149.23 | 2021-2024 | |
| Urovant Sciences INC | $125.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $100.65 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.75 | 2023 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.32 | 2024-2025 | |
| Heartflow, INC. | $43.86 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $43.65 | 2025 | Uptravi, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $43.49 | 2022 | |
| Scpharmaceuticals INC. | $43.16 | 2023-2025 | |
| Boston Scientific Corporation | $31.92 | 2025 | Farapulse |
| Amarin Pharma, INC. | $29.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.16 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $25.02 | 2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $21.07 | 2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $20.49 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $19.35 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $15.75 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.